Obefazimod

Obefazimod
Identifiers
  • 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC16H10ClF3N2O
Molar mass338.71 g·mol−1
3D model (JSmol)
  • C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F
  • InChI=1S/C16H10ClF3N2O/c17-13-3-1-2-10-4-9-14(22-15(10)13)21-11-5-7-12(8-6-11)23-16(18,19)20/h1-9H,(H,21,22)
  • Key:OZOGDCZJYVSUBR-UHFFFAOYSA-N

Obefazimod is an investigational new drug that is being evaluated for the treatment of ulcerative colitis. It is miR-124 micro RNA upregulator. Obefazimod was developed by the French biotech company Abivax SA, whose shares rose by more than 500% when the phase 3 data showed promising results.

References

  1. ↑ "Obefazimod - Abivax". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Datta N, Johnson C, Kao D, Gurnani P, Alexander C, Polytarchou C, et al. (August 2023). "MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis". Pharmacological Research. 194 106870. doi:10.1016/j.phrs.2023.106870. PMID 37499702.